Five international regulatory agencies have agreed on terms of reference for a pharmacometrics cluster aimed at fostering collaboration and scientific exchange on best practices and product development. The European Medicines Agency (EMA), the US Food and Drug Administration (FDA), Health Canada (HC), the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, and the Therapeutic Goods Administration (TGA) of Australia signed the document on 11 November 2025, published by EMA on 17 July 2026.
The cluster's objective is to exchange information and perspectives on pharmacometrics, including guidelines, workshops, publications, and products under parallel assessment, with a view to harmonising practices and activities. Participants will include staff and experts from each agency, such as EMA's Modelling and Simulation operational expert group (MSOEG) and FDA's Office of Clinical Pharmacology. The cluster will meet quarterly via teleconference, with ad-hoc meetings for urgent product-related assessments. Meetings will be chaired by the agencies on a rotating basis, with minutes circulated within three weeks.
The terms of reference outline a structured working arrangement: agenda items are called three weeks prior, topics due two Fridays before, and agendas distributed the Friday before the meeting. Each agency will rotate responsibility for preparing agendas, selecting topics of shared interest. A reminder of confidentiality will begin each meeting.
This initiative impacts pharmaceutical companies developing drugs for multiple markets, as harmonised pharmacometrics practices could streamline regulatory submissions and reduce duplication. Patients may benefit from faster access to innovative therapies if parallel assessments become more efficient. Regulatory agencies themselves stand to gain from shared expertise and reduced workload through collaboration. However, the cluster's voluntary nature and focus on exchange rather than binding decisions may limit its direct impact on approval timelines or standards. The cluster is expected to operate continuously, with potential to influence future guidelines and regulatory science globally.